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There is considerable variation in the breakpoint recommen-
dations given by various authorities for classi¢cation of anti-
microbial susceptibility results. At least six authorities provide
guidelines for susceptibility testing and breakpoint criteria in
Europe: the British Society for Antimicrobial Chemotherapy
(BSAC) [1], la Socie¨te¨ Franµ aise de Microbiologie (SFM) [2],
Deutsche Industrie Norm - Medizinische Mikrobiologie
(DIN) [3], Commissie Richtlijnen Gevoeligheidsbepalingen
(CRG) inThe Netherlands [4], the Swedish Reference Group
for Antibiotics (SRGA) [5] and the Norwegian Working
Group on Antibiotics (NWGA) [6]. In addition, guidelines
issued by the National Committee for Clinical Laboratory
Standards (NCCLS) [7] are used in many European coun-
tries.
C O M P A R I S O N O F R E S I S T A N C E R A T E S U S I N G
V A R I O U S G U I D EL I N E S
In a recent study, we investigated the antibiotic resistance
rates of Escherichia coli, Staphylococcus aureus and coagulase-
negative staphylococci (CNS) causing bloodstream infections
in two Norwegian hospitals [8]. In that study, we de¢ned
resistance according to the minimum inhibitory concentra-
tion (MIC) breakpoints of the NCCLS.We then compared the
results with those obtained when resistance was de¢ned
according to the MIC breakpoints recommended by the
NWGA for the same isolates. The percentages of susceptible,
intermediate and resistant isolates were very di¡erent for cer-
tain antibiotics.The breakpoints de¢ned by the various autho-
rities for non-fastidious organisms are presented inTable  1.To
illustrate the consequences of breakpoint variations, the per-
centages of susceptible and resistant isolates from our study of
Norwegian bloodstream infections are shown in Table  2 for
selected antimicrobials.
A few examples illustrate the di¡erences. For cefuroxime
resistance in E. coli, many isolates are classi¢ed as intermedi-
ately susceptible (76%) and resistant (9%) when applying
NWGA breakpoints, but most of these are susceptible (90%)
when applying NCCLS breakpoints.The percentages of resis-
tance using other guidelines are somewhere in between. The
susceptibility of S. aureus to oxacillin also varies considerably.
Using the British and Dutch breakpoints, 100% of our isolates
are classi¢ed as susceptible, but applying SRGA breakpoints,
15% of the isolates are classi¢ed as resistant. For the CNS, the
BSAC breakpoints classify 34% of the isolates as resistant to
methicillin, while the NCCLS classify 62% of the same iso-
lates as resistant to oxacillin.
For the following antimicrobial agents the di¡erences were
minor or absent (mostly because all isolates were susceptible):
E. coliöcefotaxime, ceftriaxone, aztreonam and cipro£oxa-
cin; S. aureusöcephalothin, imipenem, trimethoprim-sulfa-
methoxazole, clindamycin, doxycycline, teicoplanin and
rifampicin; CNSöcephalothin, imipenem, erythromycin,
clindamycin, gentamicin, teicoplanin and rifampicin.
R O L E O F B R E A K P O I N T S
Susceptibility testing is one of the most important tasks per-
formed in a medical microbiological laboratory, in addition to
identifying the etiologic agent of an infection. It is therefore
essential for susceptibility testing that the breakpoints issued
by various national committees are reliable.
Breakpoint recommendations consist of two concentra-
tions. One concentration divides the susceptible from the
intermediately susceptible bacteria and the other concentra-
tion divides the intermediately susceptible from the resistant
bacteria (SIR system). The intention has been to: `predict the
response of the patient treated with the antibacterial drug' by
applying these breakpoints [9].
When determining MIC breakpoints, many variables have
to be taken into consideration [10]. In addition to the distribu-
tion of the in vitro antibiotic susceptibility of relevant bac-
teria, pharmacokinetic properties of the drugs are
traditionally important. More recently, clinical e¤cacy has
been the focus of attention. New insights into the pharmaco-
dynamics of antibiotics may also be of importance. In addi-
tion, national therapeutic traditions and the level of resistance
prevailing in a countryor areamay be relevant.
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N E E D F O R S T A N D A R D I Z A T I O N
Our results illustrate the consequences of the di¡erent guide-
lines and MIC breakpoints proposed by the various national
authorities. As surveillance networks for collecting suscept-
ibility data at an international level are being established, the
di¡erences between guidelines have become evident. While
susceptibility data were mainly used locally or nationally,
these di¡erences were less obvious. Historically, e¡orts have
been made to set up internationally recognized guidelines,
although most of this work has been devoted to the standardi-
zation of the disk di¡usion test [11,12]. Standardization of the
test procedures and the interpretive standards has not been
achieved because of the constant addition of new antibiotics
and increased knowledge about resistance factors and new or
modi¢ed pathogens. In addition, the antibiotics licensed and
the approved indications for their use in di¡erent countries
vary.
B RE A K P O I N T D E T E R M I N A T I O N B Y N A T I O N A L
G U I D E L I N E S
The NCCLS seems to emphasize pharmacokinetics and,
more recently, clinical success as the most important criteria
for determining breakpoints, as they have wider ranges when
de¢ning their breakpoint values, resulting in fewer isolates
being classi¢ed as resistant. The two Scandinavian countries
represented here emphasize the importance of recognizing
increasing resistance early, and set their breakpoints close to
the native (often susceptible) bacterial population in order to
Table  2 Percentages of susceptible and resistant isolates for selected antimicrobials classi®ed according to the various guidelines. A Norwe-
gian blood culture material of E. coli (198 isolates), S. aureus (67 isolates) and coagulase-negative staphylococci (65 isolates) was used in
the categorization
NWGA NCCLS BSAC SFM DIN CRG SRGA
Species/antibiotic S R S R S R S R S R S R S R
E. coli
Amoxycillin 8 21 71 21 72 28 36 21 8 28 8 21 5 28
Amoxycillin/clavulanic acid ND ND 92 1 92 8 57 1 10 8 10 1 ND ND
Mecillinam 79 13 ND ND ND ND 82 13 ND ND ND ND 79 13
Cefuroxime 15 9 90 3 65 3 90 1 65 9 65 3 65 9
Trimethoprim 77 21 79 21 48 23 79 21 ND ND 72 23 77 21
Trimethoprim±sulfamethoxazole 82 17 83 17 ND ND 82 17 83 0 82 17 83 17a
Gentamicin 97 1 99 1 85 1 99 1 85 1 85 1 99 1
Doxycycline 9 60 74 20 9 91 74 20 9 26 9 26 9 60
Chloramphenicol 3 74 86 9 86 14 86 9 86 14 26 14 86 14
S. aureus
Benzylpenicillin 39 58 27 73 34 66 36 60 34 66 36 64 39 60
Oxacillin 85 3 97 3 100 0 97 3 85 15 100 0 85 15
Cefuroxime 75 0 100 0 100 0 100 0 100 0 100 0 100 0
Erythromycin 99 1 90 1 90 10 99 1 99 1 99 1 90 10
Gentamicin 85 0 100 0 75 0 100 0 75 0 75 0 100 0
Cipro¯oxacin 40 6 93 6 93 6 93 6 93 6 93 6 93 1
Chloramphenicol 0 91 69 0 0 31 69 0 69 31 9 31 69 21
Vancomycin 100 0 100 0 100 0 100 0 100 0 100 0 100 0
Fusidic acid 51 49 ND ND 78 22 81 7 ND ND 78 22 81 19
CNS
Benzylpenicillin 32 48 14 86 18 82 18 48 18 82 18 82 32 56
Oxacillin 55 37 38 62 66 34 63 37 55 45 66 34 55 45
Cefuroxime 54 40 60 31 58 31 60 25 58 40 58 31 58 40
Trimethoprim±sulfamethoxazole 44 45 45 55 ND ND 44 45 57 0 45 55 57 43a
Cipro¯oxacin 54 17 81 17 66 34 66 34 81 17 81 17 81 17
Doxycycline 38 44 64 31 58 31 64 31 39 35 39 35 38 44
Chloramphenicol 2 66 69 31 2 31 69 31 69 31 34 31 69 31
Vancomycin 98 2 98 0 98 2 98 0 98 0 98 0 98 2
Fusidic acid 35 65 ND ND 45 55 44 31 ND ND 45 55 45 55
ND, not de®ned. See Table  1 for acronyms. aDe®ned by us as complete resistance in the E test (range 0.002±32  mg/L).
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discover emerging resistance early and avoid reporting false
susceptibility [5].
The advantage of emphasizing clinical success is that clini-
cians are given guidance as to whether therapy is likely to be
successful or not. Classifying fewer isolates as resistant could
be an advantage when trying to combat antibiotic resistance.
This could prevent clinicians choosing drugs that one would
wish them not to use because they select for resistance as well
as, on occasion, having an unnecessarily broad spectrum.
However, reporting developing resistance early may lead to
the earlier application of counter-measures.
It would seem to be in the interest of the antibiotic produ-
cers that the sensitive category has a wide range, as this results
in fewer isolates being classi¢ed as resistant.
A L T E RN A TI VE S
Walker andThornsberry suggested that authors should report
MIC distributions only, instead of sensitivity groups [13]. By
selecting a system of reporting distributions only, the problem
of standardization of interpretation is avoided, but this
approach is laborious and probably less useful to clinicians
who have come to rely upon the SIR system.
Another possible solution is to change to species-speci¢c
breakpoints, as this would lead to a better correlation between
the observed MIC distribution and the resistance problems
involved. This has been suggested by the SRGA, and the sys-
tem is presently being implemented in Sweden [5]. In other
countries, species-speci¢c breakpoints are used for certain
bacteria, such as gonococci and pneumococci. Still, this sys-
tem involves grouping of bacteria into categories, and com-
parison of resistance development between areas
implementing di¡erent guidelines will remain di¤cult unless
these are standardized. Unless species-speci¢c breakpoints are
decided in international collaboration studies to make the
results obtained internationally valid, they may complicate
the situation further.
C O N C L U S I O N S
That breakpoints vary considerably between the di¡erent
guidelines seems to be the rule and not the exception. Even
themethods of giving breakpoints used by the di¡erent parties
di¡er to a degree that it makes comparison problematic. To
agree upon one single set of guidelines seems di¤cult because
of local di¡erences in antibiotic legislation and a number of
uncertainties regarding drug dose, drug concentration, MIC
and e¡ects of antibiotics. Nonetheless, international standar-
dization is most certainly needed and should be a most impor-
tant issue for international collaboration between medical
microbiologists.
Current groups that are working towards standardization
in Europe include the European Committee on Antibiotic
SusceptibilityTesting (EUCAST) [14], the EARSS (European
Antimicrobial Resistance Surveillance System) [15] and Har-
mony (Harmonization of Antibiotic Resistance Measurement
Methods in Europe). EUCAST is a subcommittee of the Eur-
opean Society for Clinical Microbiology and Infectious Dis-
eases, and EARSS and Harmony are both projects funded by
the European Commission. Standardization on a European
levelwould bemost welcome.
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